INTRODUCTION {#S1}
============

VRC01-class antibodies are potent and broad HIV-1 neutralizing antibodies (bnAbs) that offer protection from experimental animal (S)HIV (simian HIV) infection ([@R4]; [@R22]; [@R51]; [@R56]), and could be an important component of the protective immune responses elicited by an effective HIV-1 vaccine ([@R11]; [@R34]). They have been isolated from several HIV-1-infected subjects and share key genetic origins: their heavy chain (HC) V genes are derived from the VH1--2\*02 allele and are paired with light chains (LCs) expressing 5-amino acid (aa)-long CDRL3, which is rarely found in the human antibody repertoire. The 5-aa CDRL3 contains a hydrophobic residue at position 91 and a Glu96 ([@R53]; [@R67], [@R68]; [@R71], [@R72]). The VRC01-class bnAbs are extensively somatically hypermutated (up to 30% aa difference from germline) and can be up to 50% divergent in aa sequence ([@R53]; [@R67], [@R68]; [@R70], [@R72]). Despite this marked diversity, their CDR domains adopt similar overall structures and recognize the CD4-binding site (CD4-BS) of Env in a manner similar to that of CD4 ([@R70], [@R71]). Thus, despite their similar genetic origins, during chronic infection with different HIV-1 viruses, VRC01-class antibodies mature along different pathways but ultimately adopt similar structures that are associated with their broad neutralizing activity. The "structural convergent evolution" observed during natural HIV-1 infection suggests that more than one evolutionary pathway will be available to develop VRC01-class bnAbs by immunization.

Longitudinal natural viral Env variants associated with the development of bnAbs against the Env apex region ([@R14]) and of non-VRC01-class anti-CD4-BS bnAbs have been identified and characterized ([@R6]; [@R37]). Viral Envs associated with the maturation of VRC01-class antibody responses have also been reported in the case of chronic HIV-1 infection ([@R7]; [@R39]), but such viral Envs were derived from samples collected after the VRC01 B cells lineages had already expanded. More recently however, [@R61] reported on the longitudinal evolution of virus and VRC01-class B cell lineages in an HIV-1-infected patient from protocol C. So far, however, the natural Env(s) that initiated the production of VRC01-class antibodies during HIV-1 infection have yet to be identified. Also, the inferred germline forms of VRC01-class antibodies (commonly referred to as glVRC01 Abs), do not display detectable reactivity to diverse recombinant Env-derived soluble proteins ([@R27]; [@R28]; [@R41]). In recent years, we and others reported on the design of "germline VRC01-targeting" recombinant Env-derived proteins capable of binding glVRC01-class Abs ([@R28], [@R29]; [@R41], [@R42], [@R43]; [@R44]). A key feature of such immunogens is the absence of the conserved N-linked glycosylation site (NLGS) at position 276 within loop D of the gp120 Env subunit, as the N276-associated glycans present a major barrier to glVRC01 Ab binding, through steric obstruction of the germline-encoded CDRL1s ([@R8]; [@R41]; [@R71]). Mature VRC01 bnAbs accommodate this glycan by either incorporating glycine residues in their CDRL1 domains or by shortening them during affinity maturation ([@R71]).

Although VRC01 germline-targeting immunogens activate B cells engineered to express glVRC01-class B cell receptors (BCRs) *in vitro* and *in vivo* ([@R28], [@R29]; [@R41], [@R42], [@R43]; [@R44]), these cells undergo limited somatic mutation and the secreted antibodies fail to bind in the presence of N276-associated glycans on wild-type (WT) Envs ([@R15]; [@R29]; [@R43]). Efforts to guide the maturation of VRC01-like antibody responses elicited by germline-targeting immunogens through subsequent immunizations with heterologous Env-derived proteins also lacking the N276 glycans, led to increased somatic mutations, in both the VH and VL antibody genes, but no direct evidence that the elicited antibodies could accommodate N276-associated glycans was provided ([@R9]; [@R59]).

Here, we report on a two-step immunization scheme that begins with a prime immunization with the VRC01 germline-targeting prime immunogen, 426c Core, that lacks the N276 NLGS, followed by a boost immunization with a heterologous Env-derived immunogen, harboring the 276 NLGS. The outcome of this immunization scheme was the production of VRC01-like antibodies capable of accommodating the steric block imposed by the glycans present at N276 on heterologous gp120 Core-derived Envs and neutralizing the autologous, tier 2 426c virus with a modified glycan shield.

RESULTS {#S2}
=======

The 426c Core Germline-Targeting Immunogen Elicits Potent Plasma Antibody Responses against the VRC01 Epitope in Knockin Mice {#S3}
-----------------------------------------------------------------------------------------------------------------------------

We previously reported on the design of a recombinant protein derived from the inner and outer gp120 domains of the clade C Env 426c, lacking the variable domains 1, 2, and 3 as well as three NLGS at positions N276 (loop D), N460, and N463 (V5). That protein (TM4ΔV1--3, herein referred to as "426c Core" for simplicity) binds several of the known glVRC01-class Abs ([@R43]). Here, two nanoparticle forms of the 426c Core were employed as immunogens: a 5- to 7-meric form (426c Core C4b) ([@R26]; [@R43]; [@R48]) and a Ferritin-based 24-meric form (426c Core Fer) ([@R32]; [@R43]). One additional germline VRC01-targeting immunogen was investigated for its ability to engage B cells expressing glVRC01 BCRs *in vivo*: the 426c DS-SOSIP D3 ([@R8]; [@R31]). It is derived from the clade C 426c virus (like the 426c Core) and was modified by eliminating the above-mentioned three NLGSs. We also performed an immunization with the non-germline targeting unmodified 426c WT gp120 as a control.

As animal species, such as mice, rats, rabbits, or non-human primates do not express orthologs of the human VH1--2\*02 allele ([@R28]; [@R63]; [@R65]), immunizations were performed in a knockin mouse that is heterozygous for the glVRC01 HC, whereas the LCs remain the endogenous mouse LCs (mLCs) ([@R29]). Approximately 80% of naive B cells express the glVRC01 HC and 0.1% of mLCs express 5-aa-long CDRL3s. Thus, the overall estimated frequency of naive B cells expressing potential glVRC01 BCRs in this mouse model is approximately 0.08% (compared to approximately 0.01% in humans; [@R3]; [@R13]; [@R29]). The elicitation of VRC01-class bnAbs in this model requires overcoming at least two major obstacles: first, the germline-targeting immunogen must select for the B cells expressing extremely rare mLCs with a 5-aa CDRL3 paired with the glVRC01 HC, and second, the immunization regimen must lead to the accumulation of mutations that will allow the maturing B cells to bypass the obstacles presented by the N276 glycans on full-length Envs.

A single immunization with either nanoparticle form of 426c Core with two different adjuvants (poly(I:C) or GLA-LSQ) elicits robust autologous plasma antibody responses ([Figure 1A](#F1){ref-type="fig"}), the majority of which target the CD4-BS ([Figure 1B](#F1){ref-type="fig"}). Plasma antibodies generated in approximately 77% of the 426c Core-immunized animals (66 of 85), also recognized the heterologous VRC01 germline-targeting immunogen eOD-GT8 ([Figure 1C](#F1){ref-type="fig"}) in a VRC01 epitope-dependent manner ([Figures S1A](#SD1){ref-type="supplementary-material"} and [S1B](#SD1){ref-type="supplementary-material"}). eOD-GT8 is derived from the outer domain of the gp120 subunit of the clade B HxB2 Env ([@R28], [@R29]). Thus, antibodies elicited by the 426c Core that recognize eOD-GT8, but not the eOD-GT8 knockout (KO) (not recognized by VRC01-class antibodies) are most likely VRC01 epitope-specific. In contrast, the 426c DS-SOSIP D3 germline-targeting immunogen elicited very weak autologous plasma antibody responses and only one animal elicited antibodies against the 426c Core, which were non-CD4-BS directed and did not recognize eOD-GT8 ([Figure S1C](#SD1){ref-type="supplementary-material"}). Animals immunized with the non-germline-targeting Env 426c WT gp120 immunogen elicited strong autologous responses, but weak anti-426c Core antibody responses and no eOD-GT8 antibody response ([Figure S1D](#SD1){ref-type="supplementary-material"}).

We concluded that the 426c Core immunogen elicits potent anti-CD4-BS antibody responses, which recognize the VRC01 epitope.

426c Core Selects for Key Mutations in the Antibody HC and LCs {#S4}
--------------------------------------------------------------

To directly demonstrate that the 426c Core expands VRC01-lineage B cells, 2 weeks after immunization, eOD~~-~~GT8^+^/eOD-GT8 KO^−^ specific class-switched B cells from the spleens and lymph nodes (LNs) of mice displaying plasma antibody cross-reactivity to eOD-GT8 were sorted and their VH/VL genes were sequenced. eOD~~-~~GT8^+^/eOD-GT8 KO^−^ B cells were also sorted from unimmunized animals (a summary of the sequence analysis is presented in [Figure S2](#SD1){ref-type="supplementary-material"}). A total of 420 eOD-GT8+/eOD-GT8 KO^−^ class-switched B cells were singly sorted from the immunized animals and their VH and VL genes were amplified using PCR. 204 HC and 70 LCs were successfully sequenced ([Figures S2A](#SD1){ref-type="supplementary-material"} and [S2C](#SD1){ref-type="supplementary-material"}).

96% of HCs were VH1--2\*02 ([Figures 1D](#F1){ref-type="fig"} and [S2B](#SD1){ref-type="supplementary-material"}). In the majority (approximately 70%) of VH1--2\*02 HCs isolated after the prime immunization, the histidine at position 35 in the CDRH1 domain was replaced by an asparagine ([Figure S4A](#SD1){ref-type="supplementary-material"}). The H35N mutation introduces an additional hydrogen bond with N100a in CDRH3 and increases the stability of interaction between CDRH1 and CDRH3 on VRC01-class antibodies ([@R29]).

Approximately 57% of mLCs contained 5-aa-long CDRL3s ([Figures 1E](#F1){ref-type="fig"} and [S2E](#SD1){ref-type="supplementary-material"}). The majority of the 5-aa CDRL3s are derived from the mouse 8--30\*01 LC V gene, which is represented at approximately 6% in the naive eOD-GT8^+^/eOD-GT8 KO^−^ B cell repertoire ([Figures 1F](#F1){ref-type="fig"} and [S2D](#SD1){ref-type="supplementary-material"}). Other mLCs that utilized a 5-aa CDRL3 are derived from V-genes: 12--46\*01, 4--61\*01, 4--72\*01, and 6--25\*01 (representing 2.5% of the LC sequences with 5 aa each). All the identified 5-aa-long CDRL3s-containing mLCs were paired with glVRC01 HCs. Immunization with the 426c Core therefore preferentially expanded B cells expressing mLCs with 5-aa-long CDRL3s. A large fraction (40%) of the 5-aa-long CDRL3s contained a Glu96~LC~ ([Figures 1G](#F1){ref-type="fig"} and [S2F](#SD1){ref-type="supplementary-material"}), which is a key feature of mature VRC01-class antibodies and forms a hydrogen bond with Gly459~gp120~ at the N terminus of the V5 region ([@R65]; [@R71]). In contrast, 5-aa-long CDRL3s with Glu96~LC~ were not detected in the mLC sequenced from naive eOD~~-~~GT8^+^/eOD-GT8 KO^−^ B cells ([Figures 1G](#F1){ref-type="fig"} and [S2F](#SD1){ref-type="supplementary-material"}).

19 VH/VL pairs with VRC01 characteristics were expressed as IgGs (designated by "P" to indicate they were isolated following the prime immunization). All bound 426c Core and displayed no reactivity with 426c Core CD4-BS KO ([Figure 1H](#F1){ref-type="fig"}). All 19 monoclonal antibodies (mAbs) also bound the eOD-GT8 protein, but not the eOD-GT8 KO ([Figure 1I](#F1){ref-type="fig"}). As expected, the binding affinities of these antibodies for eOD-GT8 were higher than for 426c Core ([Figure S3](#SD1){ref-type="supplementary-material"}).

A 3.6-Å resolution crystal structure of antibody P-p3b3 bound to the 426c Core and a 3.2-Å resolution crystal structure of antibody P-p1f1 bound to eOD-GT8 were solved ([Figure 2](#F2){ref-type="fig"}; [Table S1](#SD1){ref-type="supplementary-material"}). These antibodies bind 426c Core and eOD-GT8 with the same angles of approach that human glVRC01 binds 426c WT Core (all atoms root-mean-square deviation \[RMSD\] = 0.3 Å for gp120-Fv) ([@R8]) or eOD-GT6 (all atoms RMSD = 0.8 Å for gp120-Fv) ([@R28]) ([Figure 2A](#F2){ref-type="fig"}). Critical contacts, both in the HC ([Figure 2B](#F2){ref-type="fig"}) and in the LC ([Figure 2C](#F2){ref-type="fig"}), were maintained in these interactions: Trp50~HC~, Asn58~HC~, Arg71~HC~, and Trp100B~HC~ residues were not mutated in the mouse VRC01-like antibodies, adopted the same orientations, and participated in the same hydrogen bonding as observed with glVRC01 ([Figure 2B](#F2){ref-type="fig"}). Similar to the human glVRC01 antibody, the short 5-aa CDRL3 of the mouse VRC01-like antibodies facilitates the interactions with gp120, and Glu96~LC~ maintains the hydrogen bonds with Gly459 and Asn280 of gp120. Only a few residues in the LC seem to contact the gp120, and they are located at the N terminus, CDRL1 and CDRL3 ([Figure 2C](#F2){ref-type="fig"}). The mouse VRC01-like antibodies have longer CDRL1 than most human VRC01-class antibodies (17 versus 11--12 aa long based on the Kabat nomenclature); however, several human VRC01-class antibodies, including VRC01c-HuGL2, have been isolated by sorting naive B cells with eOD-GT8 that contain 17-aa-long CDRL1 whose sequence is similar to that of the VRC01-like antibodies identified here ([Figure 2C](#F2){ref-type="fig"}) ([@R25]; [@R30]). Whereas the shorter CDRL1 domain of the human inferred glVRC01 Ab is well ordered in the complex of this antibody with eOD-GT6 ([@R28]) or with 426c WT Core ([@R8]), the CDRL1 of the mouse VRC01-like antibodies bound to 426c Core or eOD-GT8 and that of VRC01c-HuGL2 bound to eOD-GT8 ([@R30]) were disordered, indicating extensive CDRL1 flexibility. Such flexibility is likely necessary to accommodate glycans present on N276 in the presence of longer CDRL1. We concluded that the 426c Core immunogen elicits antibodies with similar genetic and structural features of known human VRC01-class antibodies.

Antibodies Elicited by the 426c Core Neutralize the 426c Virus Lacking the N276-Associated Glycans {#S5}
--------------------------------------------------------------------------------------------------

Eight of the above 19 mAbs were tested for binding to stabilized soluble trimeric Envs (SOSIP or NFL). None bound the autologous 426c WT DS-SOSIP ([Figure 3A](#F3){ref-type="fig"}); however, all bound to the derivative lacking the 276, 460, and 463 NLGS (426c DS-SOSIP D3) ([Figure 3B](#F3){ref-type="fig"}), and seven bound the derivative only lacking the 276 NLGS (426c ΔN276 DS-SOSIP) ([Figure 3C](#F3){ref-type="fig"}). Those seven mAbs also bound the heterologous 45_01dG5 NFL TD-2CC+(DS+) trimer ([Figure 3D](#F3){ref-type="fig"}). 45_01dG5 Env is derived from a virus that circulated in patient 45, from which several VRC01-class antibodies have been isolated (including VRC01), and naturally lacks the 276 and 460 NLGS ([@R39]). mAb P-p1e7 did not bind to autologous or ΔN276 heterologous stabilized trimeric Envs and is the only antibody of those tested that lacks Glu96~LC~ ([Figure S4](#SD1){ref-type="supplementary-material"}).

The neutralizing potency of four mAbs were evaluated against the WT 426c virus or its Δ276 NLGS derivative ([Figure 3E](#F3){ref-type="fig"}) produced in either 293T or 293 GnTI^−/−^ cells; viruses produced in 293 GnTI^−/−^ cells can be used to detect the presence of glVRC01 class antibody neutralizing activities ([@R9]; [@R35]). In agreement with the binding data, the mAbs did not neutralize the WT 426c virus (regardless of whether it was produced in 293T or 293 GnTI^−/−^ cells). However, three of four mAbs neutralized the GnTI^−/−^ produced Δ276 NLGS virus, but not when produced in 293T cells. This could be due to the fact that the shorter glycans produced in the GnTI^−/−^ cell line allow greater access of these still immature VRC01-like mAbs to the CD4-BS ([@R35]; [@R9]). The fourth, non-neutralizing antibody, P-p1e7, is the one lacking Glu~96LC~ ([Figure S4B](#SD1){ref-type="supplementary-material"}).

We concluded that the 426c Core immunogen elicits VRC01-like Abs that can recognize autologous and some heterologous soluble, stabilized Env trimers; avoiding clashes with variable regions 1, 2, and 3; and that the presence of Glu96~LC~ appears to be important for these interactions. However, although these antibodies can avoid the glycans present on the V5 Env region, their binding is impaired by the glycan at position N276 in Loop D.

Antibodies Elicited by the 426c Core Accommodate the N276 Associated Glycans on Heterologous Env Cores {#S6}
------------------------------------------------------------------------------------------------------

Plasma antibodies from 426c Core-immunized animals displayed CD4-BS-dependent recognition of heterologous monomeric WT Core proteins derived from the HxB2 (clade B), 45_01dH1 (clade B), 93TH057 (clade A/E), Q168a2 (clade A), and QH0692 (clade B) Envs ([Figure S5A](#SD1){ref-type="supplementary-material"}). These gp120-derived proteins lack the variable domains 1, 2, and 3, but harbor the N-X-T/S sequons at position N276 and in the V5 loop ([Figure S5B](#SD1){ref-type="supplementary-material"}). This observation suggested that the VRC01-like antibodies elicited by the 426c Core may bind heterologous Env Core proteins even in the presence of the N276-associated glycans.

The binding of the above-mentioned VRC01-like mAbs was examined to both the monomeric and the multimeric (C4b-based) forms of these Cores ([Figure 4](#F4){ref-type="fig"}). The mAbs exhibited very weak binding to the monomeric form of HxB2, but not the other WT Cores ([Figures 4A](#F4){ref-type="fig"}--[4E](#F4){ref-type="fig"}). However, seven of eight mAbs tested bound the multimeric forms of the HxB2 and 45_01dH1 WT Core proteins (P-p1e7 that lacks Glu~96LC~ did not bind) ([Figures 4F](#F4){ref-type="fig"}--[4G](#F4){ref-type="fig"}), and one mAb (P-p3b3) also bound the multimeric forms of 93TH057 WT Core ([Figure 4H](#F4){ref-type="fig"}), Q168a2 WT Core ([Figure 4I](#F4){ref-type="fig"}), and QH0692 WT Core ([Figure 4J](#F4){ref-type="fig"}). Mature VRC01 strongly recognized both the monomeric and multimerized forms of these Cores, while germline VRC01 did not recognize either. Hence, the 426c Core-elicited VRC01 antibodies display intermediate binding phenotypes in comparison to those of the germline and mature human VRC01 mAbs.

We conclude that a single immunization with the 426c Core elicits VRC01-like antibodies that can bypass the N276 glycans on heterologous Envs as long as the variable domains are absent (i.e., gp120-Core forms).

A Heterologous Boosting Immunization Improves the Binding Affinities of VRC01-like Antibodies to Env {#S7}
----------------------------------------------------------------------------------------------------

Based on the above observations, we hypothesized that a boosting immunization with a heterologous Core Env expressing glycans at position N276 may expand the population of B cells that are capable of bypassing the N276-associated glycans. To test this hypothesis, a new group of animals were immunized first with the C4b nanoparticle form of 426c Core and 4 weeks later with the C4b nanoparticle form of the HxB2 WT Core Env. Env-specific B cells were isolated from the spleens and LNs 2 weeks following the boost immunization and analyzed as described above. A total of 160 eOD-GT8^+^/eOD-GT8 KO^−^ B cells were isolated from these animals. 72 HCs and 79 LCs were successfully amplified and sequenced ([Figure S2](#SD1){ref-type="supplementary-material"}). The frequency of somatic mutation in the HC and LCs was higher in the antibodies isolated after the boost than after the prime ([Figures 5A](#F5){ref-type="fig"} and [S4](#SD1){ref-type="supplementary-material"}).

Fifteen antibodies (IgG) were generated from paired VH/VL sequences displaying VRC01-class antibody features. These are designated by "B" to indicate they were isolated following the boost immunization. All mAbs recognized the 426c Core immunogen used during the prime in a CD4-BS-dependent manner ([Figure 6A](#F6){ref-type="fig"}). They also bound eOD-GT8 in a VRC01 epitope-dependent manner ([Figure 6B](#F6){ref-type="fig"}). While the VRC01-like antibodies elicited following the prime immunization displayed very weak binding to the monomeric HxB2 WT Core ([Figure 4A](#F4){ref-type="fig"}), antibodies elicited after the boost, bound more strongly to several monomeric ([Figures 6C](#F6){ref-type="fig"}--[6G](#F6){ref-type="fig"}) and all multimeric WT Cores tested ([Figure S6](#SD1){ref-type="supplementary-material"}). Overall, the VRC01-like antibodies isolated after the boost have more mutations in both their HCs and LCs ([Figure 5A](#F5){ref-type="fig"}), and higher binding affinities ([Figures 5B](#F5){ref-type="fig"} and [S7](#SD1){ref-type="supplementary-material"}) than the antibodies isolated after the prime immunization.

One of the 15 antibodies (mAb B-p1b5) displayed binding to the 426c WT DS-SOSIP Env with an intact N276 glycan ([Figure 6H](#F6){ref-type="fig"}). The binding was confirmed using negative stain (ns) electron microscopy (EM), where 1--3 Fabs can be observed bound per trimer ([Figure 6I](#F6){ref-type="fig"}). A 3D nsEM reconstruction of 426c WT DS-SOSIP and B-p1b5 complex was generated in which coordinates of existing 426c DS-SOSIP D3 and glVRC01 (PDB: 6MYY) were fitted ([Figure 6J](#F6){ref-type="fig"}) ([@R8]). Weak binding of a second mAb, B-p2e2, was also observed to the 426c WT DS-SOSIP Env. Importantly, out of the four mAbs tested for neutralization, B-p1b5 neutralized the WT 426c virus (IC~50~ of 32.05 μg/mL) expressed in GnTI^−/−^ cells ([Figure 6K](#F6){ref-type="fig"}). The human germline VRC01 mAb does not neutralize this virus, suggesting that our mouse antibody is one step farther in the evolutionary pathway to VRC01. B-p1b5 also displays neutralizing activity against the heterologous tier 2 virus CH0505TF when produced in GnTI^−/−^ cells, when the loop D-associated 276 NLGS is absent ([Table S2](#SD1){ref-type="supplementary-material"}). The virus lacking 197, 276, 362, and 461/462 was neutralized, but the virus lacking only 197, 276, and 362 was not ([Table S2](#SD1){ref-type="supplementary-material"}). The neutralizing activity of B-p1b5 was abrogated by the D279K mutation ([Table S2](#SD1){ref-type="supplementary-material"}), as is the case for known human VRC01 antibodies suggesting that B-p1b5 recognizes the Env gp120 subunit in a VRC01-like manner ([@R39]). Thus, VRC01-like Abs isolated following the heterologous boost immunization have more mutations in their VH/VL domains, bind more efficiently to heterologous WT Core Envs than the antibodies isolated following the prime immunization with the 426c Core germline-targeting immunogen, and some also display autologous neutralization when the virus expresses Env with short glycans and heterologous tier 2 neutralizing activities, when certain NLGS surrounding the CD4-BS are absent. Thus, these antibodies have not yet matured sufficiently to become broadly neutralizing.

Vaccine-Elicited VRC01-like Antibodies Can Avoid Clashes with the N276-Associated Glycan {#S8}
----------------------------------------------------------------------------------------

The results in the previous section suggested, but did not conclusively prove, that the VRC01-like Abs isolated following the prime and boost immunization with 426c Core and HxB2 WT Core could more efficiently circumvent the steric hindrance imposed by the glycan at position N276 than those antibodies isolated following the prime immunization with the "germline-targeting" 426c Core immunogen.

To address this point directly, we performed a series of complementary experiments. In one experiment, B-p1b5 was co-expressed in GnTI^−/−^ cells with the 426c WT Core (which expresses the N-X-S/T sequon at position N276) as a disulfide cross-linked complex ([@R8]). The purified Ab-Env complex was further enzymatically treated with Endo H, and semiquantitative mass spectrometry analysis of the 276 NLGS was performed ([Figure 7A](#F7){ref-type="fig"}). Man5 glycans were detected at position N276, confirming that B-p1b5 binds the 426c WT Core in the presence of N276-associated glycans. Despite the additional Endo H treatment following complex formation, no (GlcNAc)~1~ glycopeptides were detected at the 276 NLGS by liquid chromatography-tandem mass spectrometry (LC-MS/MS). This observation validated that bound B-p1b5 antibody protected the N276 glycan from enzymatic digestion when interacting with its cognate epitope.

Additional experiments were performed to probe these interactions in the absence of disulfide cross-linking. In one such experiment, we used an N276-dependent mAb, 179NC75, to purify the N276-glycosylated HxB2 WT Core Env ([@R21]) ([Figure 7B](#F7){ref-type="fig"}). Purified monomeric HxB2 WT Core expressed in GnTI^−/−^ cells was incubated with 179NC75 immobilized on magnetic beads and the bound Core molecules were eluted and tested for recognition by mouse VRC01-like antibodies N-p4a9 and N-p3g9, isolated from unimmunized animals; P-p3b3, isolated following the prime immunization; and B-p1a11 and B-p1b5, isolated following the boost immunization. As expected, the antibodies isolated from unimmunized animals did not display HxB2 WT Core reactivity ([Figures 7C](#F7){ref-type="fig"} and [7D](#F7){ref-type="fig"}). P-p3b3 displayed marginal reactivity to HxB2 WT Core molecules expressing N276 glycans ("enriched") ([Figure 7E](#F7){ref-type="fig"}), while the two antibodies isolated after the boost, bound strongly to the HxB2 WT Core molecules expressing N276 glycans ("enriched") ([Figures 7F](#F7){ref-type="fig"} and [7G](#F7){ref-type="fig"}).

In another set of experiments, monomeric 426c WT Core and HxB2 WT Core proteins expressed in GnTI^−/−^ cells were incubated with magnetic beads coated with the above-mentioned mouse VRC01-like antibodies. Following immunoprecipitation, the flow-through and eluted materials were subjected to gel electrophoresis ([Figures 7H](#F7){ref-type="fig"} and [7I](#F7){ref-type="fig"}). As expected, neither 426c WT Core nor HxB2 WT Core proteins were immunoprecipitated by the N-p3g9 and N-p4a9 mAbs. 426c WT Core, but not HxB2 WT Core, was precipitated by P-p3b3. In contrast, both 426c WT Core and HxB2 WT Core were immunoprecipitated by B-p1b5. Semiquantitative mass spectrometry analysis was performed to determine the presence of Man5 glycans at position N276 in the immunoprecipitated material ([Figures 7J](#F7){ref-type="fig"} and [7K](#F7){ref-type="fig"}). This analysis confirmed that the mouse VRC01-like antibodies isolated following the prime have the potential of recognizing 426c WT Core molecules expressing N276-associated glycans and that the antibodies isolated following the boost have the potential of recognizing both the 426c WT Core and HxB2 WT Core in the presence of N276 glycans. We note that these antibodies preferentially immunoprecipitated Env molecules lacking the N276-associated glycans, a consequence of not yet being fully matured following the prime-boost immunization scheme.

Collectively, the above experiments confirm that the VRC01-like antibodies isolated following the boost immunization can accommodate N276-associated glycans on fully glycosylated heterologous gp120-derived Core proteins, but less so on trimeric Envs present on virions.

DISCUSSION {#S9}
==========

A major challenge to the successful maturation of the germline forms of VRC01 antibodies toward their broadly neutralizing forms is the steric hindrance imposed by glycan molecules present on the conserved loop D 276 NLGS. As the present germline-targeting Env-based immunogens are designed to specifically lack the 276 NLGS ([@R28], [@R29]; [@R41], [@R42], [@R43]; [@R44]), they are expected to preferentially activate BCRs that recognize the VRC01 epitope when N276-associated glycans are absent. Efforts to guide the maturation of such antibodies through sequential immunization with Env constructs also lacking 276 NLGS have so far met limited success ([@R9]; [@R59]). In the study by Tian et al., six different immunogens (only the fifth and sixth of which expressed N276-associated glycans) were sequentially administered in a knockin mouse model that expresses both the human IGHV1--2\*02 and the germline human IGKV3--20\*01 genes. mAbs isolated at the end of the immunization efficiently neutralized autologous 426c viruses lacking the N276 NLGS, and one antibody weakly neutralized the autologous 426c WT virus, which presumably had glycans occupying N276. The mechanism by which this mAb could bypass the N276-associated glycan was not reported ([@R59]). The study by Briney et al. was conducted in the same animal model we employed here, which we consider to be more stringent than the one employed by Tian, as only the glVRC01 HC is knocked in. Thus, in this model, the immunogens must first activate the rare B cells that also express a VRC01-like LC; i.e., one with 5-aa CDRL3s. Three different immunogens were administered sequentially, all three lacking N276-associated glycans. The antibodies isolated at the end of immunization efficiently neutralized heterologous viruses lacking N276-asociated glycans, and one antibody neutralized a tier 2 heterologous virus, although it is unclear whether all the virion-associated Envs express N276-associated glycans and whether and how this particular antibody bypassed the N276 glycan on this virus but not on the other viruses tested ([@R9]).

Here, we tested an alternative immunization scheme during which the prime immunization with the 426c Core germline-targeting immunogen is immediately followed by an immunization with a heterologous Core that expresses N276-associated glycans. This scheme was selected because we observed that a fraction of the VRC01-like antibodies elicited by the 426c Core immunogen display weak binding to heterologous Cores with N276 glycans. Indeed, the boost immunization improved the ability of the elicited VRC01-like antibodies to bypass the N276-associated glycans. Our observations are in agreement with reports by [@R18], [@R19]), where germline PGT121 BCRs were activated upon immunization with very low-affinity Env-derived immunogen.

The 426c Core immunogen selects for VRC01-like antibodies with key features. The H35N mutation in the CDRH1 domain leads to an increased stability between the CDRH1 and CDRH3 domains of the HC, whereas the selection of the Glu96~LC~ allows for the formation of a hydrogen bond with Gly459~gp120~ at the N terminus of the V5 region ([@R65]; [@R71]). Our data indicate that, within the 5-aa-long CDRL3 domains, the presence of Glu96~LC~ appears to be important for the antibody interactions with autologous and heterologous Core proteins. LCs with 5-aa-long CDRL3s are identifiable from naive B cells in this mouse model. However, we have not yet identified LCs with 5-aa-long CDRL3 containing a Glu96~LC~ in the BCR repertoire analysis of naive B cells from the unimmunized mice. Either these LCs are present at extremely low frequencies and our germline-targeting immunogen selects for them, or Glu96~LC~ is the result of somatic hypermutation (SHM) and subsequent selection in the germinal center following immunization with the 426c Core immunogen.

The majority of mouse VRC01-like antibodies elicited by the 426c Core, and which were subsequently boosted by the HxB2 WT Core, express LCs derived from the mouse k8--30\*01 VL gene ([Figures 1C](#F1){ref-type="fig"} and [S4B](#SD1){ref-type="supplementary-material"}), similar to what was previously reported during eOD-GT8-based immunizations in this same mouse model ([@R9]; [@R29]). As a result, their CDRL1 are 17 aa's long ([Figures 2](#F2){ref-type="fig"} and [S4B](#SD1){ref-type="supplementary-material"}). Most mature human VRC01 mAbs express shorter CDRL1s (7--11 aa long, per Kabat numbering), which sometimes contain flexible glycine residues ([@R71]). These CDRL1 features are believed to be necessary for the antibody LCs to accommodate the N276-associated glycans ([@R71]). However, several glVRC01-class antibodies isolated from naive B cells using eOD-GT8 as a bait express longer CDRL1s ([@R25]; [@R30]). One of them, VRC01c-HuGL2, recognizes eOD-GT8 in a manner similar to mature VRC01 ([@R30]) and has a CDRL1 almost identical in aa sequence as the one present in the mouse VRC01 antibodies described here ([Figure 2](#F2){ref-type="fig"}).

As compared to the rest of the VL domains, the CDRL1 regions appear to be under intense selective pressure to accumulate negatively charged aa's ([Figure S4B](#SD1){ref-type="supplementary-material"}). For instance, in most sequences, Lys30~LC~ is replaced by a glutamic acid and additional negatively charged aa's (Asp or Glu) are also introduced in that same general region of CDRL1. Although we were able to confirm that the mouse VRC01-like antibodies elicited by our vaccination strategy recognize the VRC01 epitope in the presence of N276-associated glycans, the disordered CDRL1 structures limit our understanding on how the introduction of negatively charged aa's allow these LCs to accommodate these glycans. Affinity maturation of the antibodies outside of the CDRL1 region may have compensated for the entropic cost of binding in the presence of the N276-associated glycan as has been observed in the VRC08 antibody lineage, which has a long rigid CDRL1 ([@R7]). VRC01-like antibodies that do not express k8--30\*01-derived VL domains were also isolated after the prime immunization ([Figure S4B](#SD1){ref-type="supplementary-material"}). These express shorter CDRL1 domains (10--11 aa's), but in contrast to the k8--30\*01-expressing antibodies, they were not mutated from germline, nor did they contain Glu96. So far, the neutralizing activities of mAbs isolated following the prime-boost immunization are evident against the 426c-derived virus lacking the 276 NLGS and against the heterologous CH0505TF-derived virus that not only lacks the N276 NLGS but also V5-associated NLGS (positions 461/462) ([Table S2](#SD1){ref-type="supplementary-material"}). The observation that the D279K mutation abolished the neutralizing activity of mouse VRC01-like antibodies indicates that this activity is indeed targeting the VRC01 epitope. In that case, the absence of V5-associated NLGS appears to be required for neutralization. In all cases, the potency of neutralization was higher when the target virus was expressed in 293 GnTI^−/−^ cells, an indication that the mouse VRC01-like antibodies have not yet accumulated the necessary mutations to accommodate complex glycans surrounding the CD4-BS. Presently, it is unknown whether further maturation of the mouse VRC01-like antibodies toward their broad neutralizing activities will be delayed by the presence of long CDRL1 domains.

Although approximately 0.08% of B cells express germline VRC01-like BCRs in the mouse model employed here (as compared to approximately 0.01% in humans), approximately 80% of the B cells express the already rearranged VDJ germline HC VRC01 chain ([@R29]). It will therefore be important to evaluate the prime-boost immunization protocol discussed here, at more physiological frequencies of target B cells. Such experiments would most likely require adoptive transfer of target B cells into a wild-type animal, as recently reported ([@R1]; [@R16]).

The data presented here inform how VRC01-class antibody responses may be generated during natural HIV-1 infection. It suggests that although viral Env species that initiated the expansion of precursor VRC01-class BCRs in the context of infection may either lack N276-associated glycans or have short N276-associated glycans, the subsequent viral Envs that guide the maturation of these antibodies to bypass the N276-associated glycans most likely express glycans at N276. Indeed, sequence analysis of viral Envs in patient 45 ([@R39]), from which VRC01 was isolated from ([@R67]), indicate the early presence of viral variants lacking N276-associated glycans, which were gradually replaced by viral Env variants expressing N276-associated glycans. Also, the recent report by [@R61] suggests that in the context of HIV-1 infection the development of VRC01 bnAbs may benefit from an early B cell response to Envs with N276-associated glycans. In this last study, VRC01-class lineages with preferred reactivity in the presence of N276-associated glycans were also identified.

Our study informs on how to guide the maturation of glVRC01-class antibodies during immunization, so that the immunogens employed during the boost select for antibodies with mutations that allow them to accommodate the N276-associated glycan. As such, our results are relevant to current and upcoming clinical trials that evaluate the ability of germline-targeting immunogens to elicit cross-reactive VRC01-class antibody responses.

STAR★METHODS {#S10}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S11}
---------------------------------------

Further information and requests for reagents should be directed to and will be fulfilled by Leonidas Stamatatos (<lstamata@fredhutch.org>). All reagents generated in this study can be made available upon request through Materials Transfer Agreements.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S12}
--------------------------------------

Immunizations were performed in the glH-VRC01 mouse ([@R29]). It is heterozygous for the transgene (glVRC01 HC with the CDRH3 found in the mutated antibody) and only expresses mouse light chains. The Fred Hutch Institutional Animal Care and Use Committee approved all mouse studies. Mice were 6--12 weeks old at the beginning of the studies. Both male and female mice were included in these studies. Mice were immunized intramuscularly with a dose of 60 ug of protein and 60 ug of poly(I:C) (InvivoGen, Cat\# tlrl-pic-5) split between the rear hind legs or with 50 ug of protein and 50 ul of GLA-LSQ (IDRI). Blood was collected retro-orbitally during immunization and via a cardiac puncture 2 weeks following the last immunization, at which time spleen and LNs were also harvested. Spleen and LNs were processed into a single cell suspension separately, frozen in FBS + 10% DMSO and stored in liquid nitrogen until further use. Blood, spleens and LNs were also isolated from non-immunized animals.

METHOD DETAILS {#S13}
--------------

### Protein expression and purification {#S14}

Recombinant Env proteins expressed in nanoparticle (Ferritin or C4b-based) and NFL forms were expressed and purified as previously described ([@R24]; [@R43]). Briefly, Envs were produced in 293E or 293F. Cell supernatants were purified by lectin affinity chromatography (*Galanthus nivalis*, Vector Labs), then subjected to Superdex 200 size exclusion chromatography (GE Healthcare). Ferritin nanoparticles underwent two rounds of size exclusion chromatography, first on a Superose 6 10/300GL column and then on a HiLoad 16/600 Superdex 200pg column.

Soluble trimeric SOSIP-based Envs were expressed and purified as previously described ([@R8]). In short, Env-expressing and furin-expressing plasmids were co-transfected (at 5:1 DNA ratio) into 293E cells. The Envs were purified from the cell supernatants using a Ni-affinity column followed by a Streptactin affinity column. Proteins were then subjected to enzymatic cleavage to remove the his-tag.

Monomeric proteins were produced by transfecting 293E or GnTI−/− cells with Env encoding plasmid. Cells are cultured for 6 days at 37°C, 5% CO~2~, 80% humidity, and shaking at 125 RPM. Cells were centrifuged for 3000 RPM for 30 minutes and the supernatant sterile filtered through at 0.22 uM filter. Protein was purified by passing the cellular supernatant over a 5ml Fast Flow HisTrap column (Fisher Sci, Cat \# 45000326). The eluted protein was purified on SEC as described above.

Core CD4-BS KO Env constructs contain the D368R and E370A mutations, while the eOD-GT8 KO contains the D368R mutation and the amino acids at positions 276--279 have been mutated to "NFTA."

### Flow cytometry {#S15}

Spleen and LN samples were thawed in a 37°C water bath until a small ice pellet remained in the tube and warm RPMI was then added dropwise. B cells were isolated using a mouse B cell isolation kit (EasySep, Cat\#: 19854). If the antigen-specific cells were infrequent, an antigen enrichment protocol was used during which tetramers and decoys were first added to the cells and then anti-PE microbeads (Miltenyi Biotech Cat\#: 130--048-801) and anti-APC microbeads (Miltenyi Biotech Cat\#: 130--090-855) were added. Stained cells were then flowed over LS Columns (Miltenyi Biotec Cat\#: 130--042-401) to separate the antigen-specific cells from the non-antigen specific. The B cells were then stained with a combination of the following antibodies: IgG1 FITC (BD Biosciences Cat\#: 553443), IgG2b FITC (BD Biosciences Cat\#: 553395), IgG2c FITC (Bio-Rad Cat\#: STAR135F), IgG3 FITC (BD Biosciences Cat\#: 553403), IgD PerCP-Cy5.5 (Biolegend Cat\#: 405710), GL7 eFluor 450 (Thermo Fisher Scientific Cat\#: 48--5902-80), eBioscience Fixable Viability Dye eFluor 506 (Thermo Fisher Scientific Cat\#: 65--0866-14), CD3 BV510 (BD Biosciences Ct\#: 563024), CD4 BV510 (BD Biosciences Cat\#: 563106), Ly-6G/Ly-6C BV510 (BD Biosciences Cat\#: 563040), F4/80 BV510 (BD Biosciences Cat\#: 123135), IgM BV605 (Biolegend Cat\#: 406523), B220 BV786 (BD Biosciences Cat\#: 563894), CD38 AF700 (Thermo Fisher Scientific Cat\#: 56--0381-82), CD19 BUV395 (BD Biosciences Cat\#: 563557) or CD19 BV650 (BD BiosciencesCat\#: 563235).The cells were stained with either 426c DMRS Core/426c DMRS DREA (D368R and E279A) Core or eOD-GT8/eOD-GT8 KO tetramers to select for Env specific and CD4-BS specific B cells. Tetramers were made by combining biotinylated Env with Streptavidin conjugated to either a PE or APC fluorophore (Prozyme, PJFS25 and PJ27S). From the groups of immunized mice, only samples from animals which showed eOD-GT8 plasma cross-reactivity were used for sorting.

### Single B cell sorting {#S16}

Naive, antigen-specific B cells were sorted as CD3−, CD4−, Gr-1−, F4/80−, B220+, CD19+, antigen+/antigen KO−. Class-switched IgG B cells from immunized animals were sorted based on the following markers: CD3−, CD4−, Gr-1−, F4/80−, B220+, CD19+, IgG1+, IgG2b+, IgG2c+, IgG3+, antigen+/antigen KO-. Individual B cells were sorted using the FACS ARIA II into a 96 well plate containing 20 ul of lysis buffer (20 U of RNase out (Thermo Fisher Scientific, Cat\#: 10777019), 5 ul 5X Superscript IV RT buffer, 1.25 ul of 0.1M DTT, 0.625 ul of 10% Igepal, 13 ul nuclease free H~2~0) in each well. Plates with the sorted cells were stored at −80°C until further processing.

### PCR amplification and sequencing of VH and VL genes {#S17}

RNA was reverse transcribed to cDNA. For the reverse transcription reaction, 0.1 ul of Random Primers (3ug/ul, ThermoFisher Scientific Cat\#: 48190011), 2 ul 10mM GeneAmp dNTP Blend (ThermoFisher Scientific, Cat\#: N8080261), 1 ul SuperScript IV RT (200 U, ThermoFisher Scientific Cat\#: 18090200), and 2.9 ul of nuclease free H~2~0 was added to the wells containing lysed cells. The reaction was run on a thermocycler for 10 minutes at 42°C, 10 minutes at 25°C, 60 minutes at 50°C, and 5 min at 94°C. Following reverse transcription, the cDNA was diluted 1:2. Two rounds of PCR were employed to amplify both VH and VL genes. Each PCR reaction contains: 7 ul of cDNA, 2.4 units of HotStar Taq Plus (QIAGEN, Cat\#: 203607), 240 nM of 5′ and 3′ primer, 350 uM GeneAmp dNTP Blend (Thermo Fisher Scientific, Cat\#: N8080261), 4 ul of 10X buffer, and 27.8 ul nuclease free H~2~0. All primers and cycling conditions can be found in [Tables S3](#SD1){ref-type="supplementary-material"} and [S4](#SD1){ref-type="supplementary-material"}. After the second round of PCR, samples were subjected to electrophoresis on a 1.5% agarose gel containing 0.1% Gel Red Nucleic Acid Stain (Biotium, Cat\#: 41002). cDNA was purified using the enzyme ExoSap-IT (Affymetrix, Cat\#: 78201). The purification reaction contained 5 ul of second round PCR product and 2 ul of ExoSap-IT. This reaction was run on a thermocycler for 15 min at 37°C followed by 15 min at 80°C. Following enzymatic purification, 5 ul of 5 uM second round 5′ primer was added to the sample and 3 ul of nuclease free water. Samples underwent sanger sequencing to identify the DNA sequence (Genewiz, Seattle, WA). Upon receiving the sequence, IMGT/V-QUEST was used to assign V, D, and J gene identity to the sequences and CDRL3 length ([@R10]; [@R23]). Sequences were included in the analysis ([Figure S2](#SD1){ref-type="supplementary-material"}) if they had an identifiable CDR3 region.

Amino acid mutations were identified by aligning the VH/VL gene sequences to the corresponding germline genes (IMGT Repertoire) using the Geneious Software (Version 8.1.9). For VL, mutations were counted beginning at the 5′ end of the V-gene to the 3′ end of the FW3. For VH, mutations were counted beginning at the 5′ end of the V-gene to the end of the KI gene. See [Figure S4](#SD1){ref-type="supplementary-material"} for sequence alignments. To quantify the number of amino acid mutations, the sequence alignments were exported from Geneious and imported into R (Version 3.4.1) for analysis ([@R52]). This analysis uses the packages Biostrings ([@R50]), seqinr ([@R12]), and tidyverse ([@R66]). The sequences and code for this analysis can be found here: <https://github.com/krparks/glVRC01_sequential_immunization>.

### VH and VL cloning and antibody expression {#S18}

Gene-specific PCR was used to amplify the DNA product from the first round PCR using primers designed to anneal to the gene of interest as well as add ligation sites to facilitate insertion of the DNA fragment into the human IgG1 vector \[ptt3 k for kappa ([@R57]), and PMN 4--341 for gamma ([@R47])\]. Each gene specific PCR reaction contained 0.5 ul each of 10 uM 5′ and 3′ primer, 22.5 ul Accuprime Pfx Supermix (Cat\#: 12344040), and 1.5 ul of 1^st^ or 2^nd^ round PCR product. The gene-specific PCR product was infused into the cut IgG1 vector in a reaction containing 12.5 ng of cut vector, 50 ng of insert, 0.5 ul of 5X Infusion enzyme (InFusion HD Cloning Kit, Cat\#: 639649), and nuclease-free water to bring volume to 2.5 ul. The entire reaction was used to transform competent *E. coli* cells and plated on agar plates containing ampicillin. In some cases, gBlocks were synthesized to make the VH or VL containing plasmid (GenScript). 60 ng of glBlock was added to 15 ng of cut vector and 0.5 ul of 5× In-Fusion enzyme (Takara, Cat\#: 1805251A). This reaction was run on the thermocycler for 15 min at 50°C. The entire reaction was used to transform competent *E. coli* cells (New England Biolabs, Cat\#: C2987HI) and plated on agar plates containing ampicillin. Once a colony containing the insert sequence was identified, it was grown in LB broth containing ampicillin. DNA was prepared using QIAprep Spin Miniprep Kit (QIAGEN, Cat\#: 27106). Equal amounts of heavy and light chain DNA and 293F transfection reagent (Millipore Sigma, Cat\#: 72181) were used to transfect 293E cells. 5--7 days post transfection cell supernatants were collected, and the antibodies were purified using Pierce Protein A agarose beads (Thermo Fisher Scientific, Cat\#: 20334). The antibodies were eluted using 0.1 M Citric Acid into a tube containing 1 M Tris. The antibodies were buffer exchanged into 1XPBS using an amicon centrifugal filter.

To make Fabs, the IgG was cleaved overnight at 37°C to generate antigen binding fragment (Fab) with Endoproteinase Lys-C (NEB). To remove undigested IgG and IgG Fc fragments, the mixture was incubated with Protein A Agarose Resin for 1 hour at room temperature. Beads were washed with 1X PBS to remove excess Fab. Fab was further purified on SEC using a HiLoad 16/600 Superdex 200 pg (GE) column.

### Protein Production for Structural Studies {#S19}

#### P-p1f1Fab and eOD-GT8 (PDB ID: 6P8N) {#S20}

eOD-GT8 was expressed in HEK293S GnTI−/− cells. Cells were cultured in suspension and transfected using 500 μg eOD-GT8 plasmid with 293 Free Transfection Reagent (Novagen) in 1 L. After 6 days, cells were centrifuged at 4,500 rpm for 20 min and supernatant was filter-sterilized. A His-tag was utilized for purification by adding His60 Ni-Superflow Resin (Takara, Cat \#:636660) in the supernatant at 4°C overnight. Ni Resin was washed with a solution of 150mM NaCl, 20 mM Tris pH 8.0, 20 mM Imidazole pH 7.0 and eluted with a solution of 300 mM NaCl, 50 mM Tris pH 8.0, 250 mM Imidazole pH 7.0. Protein was further purified using SEC as previously described. Complexes of eOD-GT8 and P-p1f1Fab were made by mixing equal molar ratio of both proteins for 1 hour at room temperature. Complexes were then mixed with Endo H (NEB, Cat\#: P0702S) for 1hour at 37°C. SEC was used to remove any uncomplexed protein and Endo H. Complexes were concentrated to \~10 mg/mL for crystallization trials.

#### P-p3b3Fab and 426c Core (PDB ID: 6P8M) {#S21}

P-p3b3Fab crosslinked to 426c Core was expressed in HEK293S GnTI−/− cells. Cells were cultured in suspension and transfected with equal parts of 426c Core G459C, P-p3b3Fab-A60C heavy chain, and P-p3b3 light chain plasmids (500 μg total/L) as previously described ([@R8]). Complexes were purified with a His tag on the Fab heavy chain C terminus followed by SEC to remove nonspecific proteins and excess unliganded Fab. An SDS gel was run on the complex to confirm the disulfide bond formation between the P-p3b3fab and the 426c Core. Complexes were treated with EndoH (New England Biolabs, Cat\#: P0702S) for 1hr at 37°C and run on SEC to remove Endo H. Complexes were concentrated to \~10 mg/mL for crystallization trials.

### Crystallization {#S22}

Crystallization conditions were screened and monitored with an NT8 drop setter and Rock Imager (Formulatrix). Screening was done with Rigaku Wizard Precipitant Synergy block no. 2 (MD15-PS-B), Molecular Dimensions Proplex screen HT-96 (MD1--38), and Hampton Research Crystal Screen HT (HR2--130) using the sitting drop vapor diffusion method. P-p1f1fab + eOD-GT8 crystals were further optimized with hanging drop trays using vapor diffusion method. Final crystals for P-p1f1fab + eODGT8 were grown in 22.5% PEG 3350, 13.5% Isopropanol, 0.18M Ammonium Citrate pH 4.0. Final crystals for P-p3b3fab + 426c Core were grown in 0.67% PEG 4000, 0.67M Ammonium Citrate pH 5.5. P-p1f1fab + eODGT8 crystal were cryo protected in a solution of 20% molar excess of the crystallization condition and 20% Ethylene Glycol. P-p3b3fab + 426c Core were cryoprotected in the original crystallization condition. P-p3b3fab + 426c Core and P-p1f1fab + eODGT8 were sent to ALS 5.0.2 and diffraction data was collected to 3.59 Å and 3.2 Å respectively. Data were processed using HKL2000 ([@R49]).

### Structure Solution and Refinement {#S23}

The structure of P-p1f1Fab + eOD-GT8 was solved by molecular replacement using PDB ID: 4JPK as a search model in Phaser in Phenix. The structure of P-p3b3Fab + 426c Core was solved by molecular replacement using PDB ID: 6MFT as a search. The structures were further refined with COOT ([@R17]) and Phenix ([@R2]). The refinement statistics are summarized in [Table S1](#SD1){ref-type="supplementary-material"}.

### Negative-stain EM {#S24}

The 426c WT DS-SOSIP/B-p1b5 complex was formed by co-incubating B-p1b5 Fab to 426c WT DS-SOSIP trimer at a 2:1 B-p1b5:gp120 monomer ratio (alternatively referred to as 6:1 B-p1b5 trimer ratio) ratio for 10 minutes at 4°C. Samples treated with glutaraldehyde were cross-linked in 0.25% GTA for 45 s followed by quenching with 1M Tris, followed by purification of bound complexes via a Superdex 200 10/300 GL Increase column. 426c WT DS-SOSIP/B-p1b5 Fab complexes examined in this study (3 μL) were negatively stained at a final concentration of 0.010 mg/mL using Gilder Grids overlaid with a thin layer of carbon and 2% uranyl formate (Electron Microscopy Sciences, Cat\#: 22451) as previously described ([@R62]).

Data were collected on an FEI Technai 12 Spirit 120kV electron microscope equipped with a Gatan Ultrascan 4000 CCD camera. A total of \~300 images were collected per sample by using a random defocus range of 1.1--2.0 μm with a total exposure of 45 e−/A^2^. Data were automatically acquired using Leginon ([@R58]) and data processing was carried out using Appion ([@R36]). The parameters of the contrast transfer function (CTF) were estimated using CTFFIND4 ([@R45]), and particles were picked in a reference-free manner using DoG picker ([@R64]). Particles were extracted with a binning factor of 2 after correcting for the effect of the CTF by flipping the phases of each micrograph with EMAN 1.9 ([@R38]). The GTA cross-linked 426c WT DS-SOSIP B-p1b5 Fab stack was pre-processed in RELION/2.1 ([@R33]; [@R54], [@R55]) with an additional binning factor of 2 applied, resulting in a final pixel size of 6.4 Å. Resulting particles were sorted by reference-free 2D classification over 25 iterations. The best particles were chosen for 3D classification into 2 classes using C1 symmetry in RELION/2.1 ([@R33]). The best class of particles were refined using Relion/3.0 ([@R73]).

### Biolayer Interferometry (BLI) {#S25}

Antibody binding to recombinant Env proteins was determined using biolayer interferometry on the Octet Red 96 (ForteBio, Inc, Menlo Park, CA), as previously described ([@R69]). Briefly, anti-human Fc capture biosensors (ForteBio, Cat\#: 18--5063) were activated by immersion into 1× Kinetics Buffer (1× PBS, 0.1% BSA, 0.02% Tween-20, 0.005% NaN~3~) for 10 minutes. Antibodies were loaded onto an anti-human Fc capture probe at 20 ug/ml. The probes were then dipped into solutions containing recombinant Env: 2 uM for monomeric gp120-derived Envs or 1 uM for C4b and trimeric Env (SOSIP or NFL designs). Parameters for all BLI assays were: 30 s of baseline measurement, 240 s to load the antibody onto the anti-human Fc capture probe, 60 s of baseline measurement, 300 s of association, 300 s of dissociation. All measurements of Env-Ab binding were corrected by subtracting the background signal obtained from env traces generated with an irrelevant negative control IgG.

Kinetic analyses were performed by BLI as described above using recombinant Fabs loaded onto FAB2G biosensors (ForteBio, Cat\#: 18--5126) (@ 40 ug/ in 1XPBS) and 2-fold dilutions of envelope monomers (ranging from 50 uM - 391 nM), and by extending the dissociation phase of binding to 600 s. Curve fitting was used to determine relative apparent antibody affinities for envelope using a 1:1 binding model and the data analysis software (ForteBio). Mean k~on~, k~off~, and K~D~ values were determined by averaging all binding curves within a dilution series having R^2^ values of greater than 95% confidence level.

### Enzyme linked immunosorbent assays {#S26}

Plasma samples were heated inactivated at 56°C for 1 hour, centrifuged at 13,000 for 10 min and stored at 4°C or −20°C. ELISAs were done in either a half-area 96 well or 384 well plate format. For a 384 well plate ELISA, 30 ul of protein at 0.1 uM in coating buffer (0.1M sodium bicarbonate, pH: 9.4--9.6) was added to each well and incubated a room temperature overnight. Plates were washed 4× with ELISA wash buffer (1XPBS + 0.2% Tween-20). 80 ul of blocking buffer (1X PBS + 10% non-fat milk + 0.03% Tween20) was added to the plates and they were incubated at 37°C for 1--2 hours. Plates were then washed 4× with ELISA wash buffer. Plasma was diluted 1:10 in blocking buffer and diluted 1:3 across or down the plate. His tag control started at 1 μg/ml. The plates were incubated for 1 hour at 37°C. The plates were washed 4× with ELISA was buffer. 30 ul of secondary antibody was added to each well. The plates were incubated for an hour at 37°C. Plates were washed 4× with ELISA wash buffer. Following washing 30 ul of SureBlue Reserve TMB Microwell Peroxidase Substrate: KPL (Cat \#: 53--00-02) was added to each well. The plates were incubated for 5 minutes at room temperature. 30 ul of 1N H~2~SO~4~ was added to each well. Plates were read immediately on the SpectraMax M2 microplate reader (Molecular Devices) at 450 nm. Blank wells were used to subtract the background signal in the analysis. 96 well plate ELISAs followed a similar protocol but used 50 ul of volume for the coating of protein, dilution volumes, secondary antibody volume, and development steps. 120 ul of blocking buffer was used to block the plates.

### Neutralization assays {#S27}

Neutralizing antibody activity was measured in 96-well culture plates by using Tat-regulated luciferase (Luc) reporter gene expression to quantify reductions in virus infection in TZM-bl cells. TZM-bl cells were obtained from the NIH AIDS Research and Reference Reagent Program, as contributed by John Kappes and Xiaoyun Wu. Assays were performed with HIV-1 Env-pseudotyped viruses as described previously ([@R46]). For the assays, mAbs were used at 100 ug/ml or the highest concentration possible. Samples were then diluted over seven 3-fold dilutions and pre-incubated with virus (\~150,000 relative light unit equivalents) for 1 hr at 37°C before addition of cells. Following an additional 48 hr incubation, cells were lysed and Luc activity determined using a microtiter plate luminometer and BriteLite Plus Reagent (PerkinElmer, Cat\#: 6066766). Neutralization titers are the antibody concentration at which relative luminescence units (RLU) were reduced by 50% compared to RLU in virus control wells after subtraction of background RLU in cell control wells.

### Immunoprecipitation {#S28}

Purified recombinant IgGs were covalently coupled to MyOne Tosylactivated Dynabeads (Thermo Fisher Scientific, Cat\#: 65501). Coupling and Env-immunoprecipitation were carried out according to the manufacturer's protocol. Briefly, 5 mg of Env produced in HEK293S GnTI^−/−^ were incubated with 200 μg of IgG-beads for 30 min. The IgG-Env protein complexes were then precipitated using magnetic separation and washed 3--4× before performing acidic elution and pH neutralization of the bound material. Env-samples of the original input of 426c WT Core or HxB2 WT Core, and bead-bound/eluted and unbound fractions were subjected to SDS gel electrophoresis under reducing conditions. A sample of the bound fractions were subjected to LC-MS/MS analysis or used for BLI.

### Mass spectrometry {#S29}

For analysis of the *N*-linked glycosylation profile of the cross-linked 426c WT Core-P1B5 complex, 250 pmol of sample was denatured, reduced, and alkylated by dilution to 5 μM in 50 μL of buffer containing 100 mM Tris (pH 8.5), 10 mM Tris (2-carboxyethylphosphine (TCEP), 40 mM iodoacetamide or 40 mM iodoacetic acid, and 2% (wt/vol) sodium deoxycholate. Samples were first heated to 95°C for 5 min and then incubated for an additional 25 min at room temperature in the dark. The samples were digested with trypsin (Thermo Fisher Scientific, Cat\#: 90057), by diluting 20 μL of sample to a total volume of 100 μL of buffer containing 50 mM ammonium bicarbonate (pH 8.5). Trypsin was added in a ratio of 1:50 (w/w) before incubation at 37°C overnight. Subsequently, 2 μL of formic acid was added to precipitate the sodium deoxycholate from the solution. Following centrifugation at 17,000 × g for 25 min, 85 μL of the supernatant was collected and centrifuged again at 17,000 × g for 5 min to ensure removal of any residual precipitated deoxycholate. 80 μL of this supernatant was collected. For each sample, 8 μL was injected on a Thermo Scientific Orbitrap Fusion Tribrid mass spectrometer. A 35 cm analytical column and a 3 cm trap column filled with ReproSil-Pur C18AQ 5 μM (Dr. Maisch) beads were used. Nanospray LC-MS/MS was used to separate peptides over a 90 min gradient from 5% to 30% acetonitrile with 0.1% formic acid. A positive spray voltage of 2100 was used with an ion transfer tube temperature of 350°C. An electron-transfer/higher-energy collision dissociation ion-fragmentation scheme ([@R20]) was used with calibrated charge-dependent entity-type definition parameters and supplemental higher-energy collision dissociation energy of 0.15. A resolution setting of 120,000 with an AGC target of 2 × 10^5^ was used for MS1, and a resolution setting of 30,000 with an AGC target of 1 × 10^5^ was used for MS2. Data were searched with the Protein Metrics Byonic software ([@R5]), using a small custom database of recombinant protein sequences including the proteases used to prepare the glycopeptides. Reverse decoy sequences were also included in the search. Specificity of the search was set to C-terminal cleavage at R/K (trypsin), allowing up to three missed cleavages, with EthcD fragmentation (b/y- and c/z-type ions). We used a precursor mass and product mass tolerance of 12 ppm and 24 ppm, respectively. Carbamidomethylation of cysteines was set as fixed modification, carbamidomethylation of lysines was set as a variable modification, methionine oxidation as variable modification, and a concatenated N-linked glycan database (derived from the four software-included databases) was used to identify glycopeptides. All analyzed glycopeptide hits were manually inspected to ensure their quality and accuracy.

Semiquantitative LC-MS/MS of P-p3b3, B-p1b5 and VRC01-immunoprecipitation experiments were performed using Skyline ([@R40]) with peak integration and LC-MS/MS searches imported from Byonic, as previously described ([@R8]). Missed cleavages and post-translational modifications listed above for qualitative LC-MS/MS searches were included in the quantification of glycopeptides. All MS1 peak areas used for integration were manually inspected. Each fraction was performed as part of two technical replicates and was subsequently averaged. Calculations and plots for glycoform enrichment graphs were generated by subtracting the relative signal values of the input Core fraction from the unbound or bound Core fractions.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S30}
---------------------------------------

Mean and standard deviations were calculated using R (Version 3.4.1). Statistical analyses were calculated using R (Version 3.4.1) ([@R52]) and GraphPad Prism. Descriptions of the statistical methods used for each dataset are described in the figure legends. The tidyverse packages ([@R66]) were used in R to manipulate data and create graphs in addition to GraphPad Prism.

DATA AND CODE AVAILABILITY {#S31}
--------------------------

The sequences of mAbs reported here have been deposited on GenBank and in the GitHub respository: <https://github.com/krparks/glVRC01_sequential_immunization>. The accession numbers of the mAb sequences are GenBank: [MN087228](MN087228) - [MN087315](MN087315) ([Table S5](#SD1){ref-type="supplementary-material"}). Multimeric and monomeric heterologous Env sequences have been deposited on GenBank, accession numbers GenBank: [MN179660](MN179660)-[MN179671](MN179671) ([Table S5](#SD1){ref-type="supplementary-material"}). Coordinates and structure factors have been deposited on the Protein Data Bank under PDB: 6P8N and PDB: 6P8M. Raw and analyzed Mass Spectrometry data have been deposited on PRIDE. The accession number for the mass spectrometry data is PRIDE: PXD015168.
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![426c Core Elicited Antibody and B Cell Response\
(A and B) Plasma from representative animals immunized with 426c Core C4b (gray) or 426c Core Fer (black) were tested for binding against (A) 426c Core and its (B) CD4-BS KO form.\
(B) Summarizes the data from one experiment with 10 animals in each group. A paired t test was used to determine statistical significance between the mean EC~50~ titers against the 426c Core versus those against its CD4-BS KO.\
(C) Summary of the animal frequencies per group of 426c Core-immunized animals that developed anti-eOD-GT8 plasma antibody responses (OD 450 nm of ≥ 0.1 at 1:10 dilution; additional information is provided in [Figure S1](#SD1){ref-type="supplementary-material"}). The nanoparticle form and the adjuvant used is indicated. The number of animals that developed anti-eOD-GT8 responses out of the total immunized for each group is indicated within each bar.\
(A--C) At least two biological replicates were performed for each immunization group (multimer + adjuvant).\
(D--G) Pie charts indicate HC and LC sequences from individually sorted B cells from immunized (3 independent experiments) and non-immunized animals (1 experiment). The number of sequences analyzed is shown in the middle of each pie chart.\
(D) HC sequences from naive and immunized animals.\
(E) aa length of the CDRL3 domains in the sequences from the naive and immunized animals. 5-aa-long CDRL3s are shown in green.\
(F) V-gene usage of the LCs from the sequences isolated from naive and immunized animals. The 8--30\*01 V-gene is shown in pink.\
(G) Presence or absence of Glu96~LC~ within the LC sequences with 5-aa-long CDRL3 domains. mAbs with VRC01 characteristics were generated from paired VH/VL sequences from class-switched B cells isolated following the prime immunization (indicate by "P") with the 426c Core.\
(H) mAb binding to monomeric 426c Core (colored lines) and to monomeric 426c Core CD4-BS KO (gray lines).\
(I) mAb binding to monomeric eOD-GT8 (colored lines) and to monomeric eOD-GT8 KO (gray lines). Data are representative of 1--2 experiments.](nihms-1545816-f0002){#F1}

![Structural Information of VRC01-like Antibodies Isolated after Immunization with the 426c Core Env\
(A) Structures of P-p1f1 (shades of blue) in complex with eOD-GT8 (green) and P-p3b3 (shades of pink) in complex with 426c Core (gray) are shown in cartoon representation (left). These two structures are superimposed onto the structure of glVRC01 (shades of yellow) bound to 426c WT Core (orange) (PDB: 6MFT) (right). The structures are shown in ribbon representation and only the Fv portion of the Fab is shown for clarity. The glycan present at N276 in the structure of 426c WT Core bound to glVRC01 is shown in stick.\
(B) Zoom insets of important contact residues in the HC of glVRC01 and VRC01-like mouse antibodies. HC sequence alignments of glVRC01, P-p1f1, P-p3b3,and VRC01c-HuGL2. Residues within 5 Å of each respective antigen are shown with an asterisk under the alignment.\
(C) LC sequence alignments of glVRC01 (k3--20), P-p1f1, P-p3b3, and VRC01c-HuGL2. Residues within 5 Å of each respective antigen are shown with an asterisk under the alignment. Zoom insets of the LC N terminus, CDRL1 and CDRL3 contacts. The glycan at N276 present in the structure of glVRC01 bound to 426c WT Core is shown in sticks (PDB: 6MFT). Disordered CDRL1s are drawn in dotted lines.](nihms-1545816-f0003){#F2}

![Trimeric Env-Binding and Neutralizing Properties of VRC01-like Antibodies Elicited by the 426c Core Germline-Targeting Immunogen\
(A--D) The binding of eight VRC01-like antibodies generated following the prime immunization against (A) the autologous 426c WT DS-SOSIP; (B) its variant that lacks the N276, N460, and N463 NLGS (426c DS-SOSIP D3); (C) a variant that only lacks the N276 glycan (426c Δ276 DS-SOSIP); and (D) the heterologous 45_01dG5 NFL TD-2CC+(DS+), which also lacks the N276 NLGS, was measured using Biolayer interferometry. Data are representative of 1--2 experiments.\
(E) EC~50~ neutralizing titers (μg/ml) of four mAbs tested against the autologous WT 426c virus and its variant lacking the 276 NLGS, grown in either 293T cells or in 293S GnTI^−/−^ cells. Mature VRC01 and glVRC01 mAbs were used as controls during these experiments. nt, not tested.](nihms-1545816-f0004){#F3}

![VRC01-like Antibodies Elicited by the 426c Core Germline-Targeting Immunogen Recognize Heterologous Wild-Type Core Env Proteins\
(A--J) Biolayer interferometry binding traces of the indicated mAbs to the indicated Env proteins in either monomeric (A--E) or nanoparticle (C4b based) (F--J) forms (data are representative of 2 technical replicates). Mature and germline VRC01 mAbs were used as controls.](nihms-1545816-f0005){#F4}

![VH/VL Mutations and Binding Affinities of VRC01-like Antibodies Isolated throughout the Immunization\
(A) The number of aa mutations per each VH and VL domains in mAbs generated from sequences isolated following the prime immunization with 426c Core and the boost immunization with HxB2 WT Core are shown (see [Figure S4](#SD1){ref-type="supplementary-material"} for VH and VL sequence alignments). Each dot represents a sequence. A Welch two-sample t test (unpaired t test) was used to determine the statistical significance. Error bars show SD from the mean.\
(B) The binding affinities of antibodies (Fabs) isolated from naive, non-immunized animals (red) and antibodies generated after the prime immunization (blue) and following the boost immunization (green) are shown for the 426c WT Core and the HxB2 WT Core (binding traces and summary affinity information are shown in [Figure S7](#SD1){ref-type="supplementary-material"}).](nihms-1545816-f0006){#F5}

![Env-Recognition and Neutralizing Properties of VRC01-like Antibodies Isolated following the Boost Immunization with the HxB2 WT Core Env\
(A--H) Biolayer interferometry binding traces of the indicated VRC01-like mAbs isolated after the boost immunization (prefix: B) to the monomeric Env Core proteins: 426c Core (A), HxB2 WT Core (C), 45_01dH1 WT Core (D), 93TH057 WT Core (E), Q168a2 WT Core (F), QH0692 WT Core (G); monomeric eOD-GT8 (B); and the 426c WT DS-SOSIP trimeric Env (H). Mature VRC01 (green) and germline VRC01 (dashed pink) were used as controls.\
(I) ns EM analysis of the 426c WT DS-SOSIP/B-p1b5 complex. Raw micrographs (scale bar, 200 nm) and 2D class averages (scale bar, 90 Å) of B-p1b5 bound to 426c WT DS-SOSIP trimers following a mild glutaraldehyde cross-linking (0.25% GTA for 45 s followed by quenching with 1 M Tris) to increase saturation of the 426c WT DS-SOSIP trimer.\
(J) 3D reconstruction of the negatively stained 426c WT DS-SOSIP/B-p1b5 complex cross-linked with 0.25% GTA. Structures of the 426c DS-SOSIP D3 trimer and germline VRC01 Fab were fit to the density as a reference (gray, ns EM density; blue, 426c DS-SOSIP D3; yellow, Fab) ([@R8]).\
(K) EC~50~ neutralizing titers (in micrograms per milliliter) of indicated mAbs against the WT 426c virus grown in either 293T cells of 293S GnTI^−/−^ cells. Mature and germline VRC01 mAbs were used as controls for the binding and neutralization assays. Neutralization assays against the GnTI^−/−^ produced virus were performed 2--3 times. Neutralization assays against the 293T produced virus is from one experiment. nt, not tested.](nihms-1545816-f0007){#F6}

![Vaccine Elicited Antibodies Bind in to Env Core with Glycans at N276\
(A) The 426c WT Core/B-p1b5 complex was generated in 293 GnTI^−/−^ cells, purified, and subjected to semiquantitative LC-MS/MS analysis. Depicted here are the relative signal intensities of (glyco)peptides comprising the 276 NLGS. The mass spectrometry data represent the average of two technical replicates.\
(B) Binding of mAb 179NC75 to HxB2 WT Core or its derivative lacking the N276 NLGS ("HxB2 WT Core Δ276"). Data are representative of two technical replicates.\
(C--G) Binding of the mAbs N-p4a9 (C), N-p3g9 (D), P-p3b3 (E), B-p1b5 (F), and B-p1a11(G) to HxB2 WT Core that has been enriched for the glycan at 276 (eluted from a 179NC75 column) or the unenriched fraction.\
(H and I) mAbs generated from unimmunized animals (N-p3g9 and N-p4a9), from animals immunized with the 426c Core (P-p3b3), and from animals immunized with the 426c Core and the HxB2 WT Core (B-p1b5) were immobilized on beads. The beads were incubated with 426c WT Core or HxB2 WT Core proteins expressed in 293 GnTI^−/−^ cells. Following co-immunoprecipitation, 426c WT Core (H) and HxB2 WT Core (I) were washed and eluted from the beads. (H and I) A fraction of the unbound ("−") and the eluted ("+") material was subjected to SDS-PAGE gel electrophoresis. The gel is representative of two technical replicates. (J and K) The eluted fractions were further subjected to semiquantitative LC-MS/MS analysis (two technical replicates) to determine the presence of a glycan at position 276 on 426c WT Core (J) and on HxB2 WT Core (K). The quantity of material eluted from the beads after co-immunoprecipitation is shown in the middle of the pie charts, which are scaled relative to the amount of material pulled down with mature VRC01.](nihms-1545816-f0008){#F7}

  REAGENT or RESOURCE                                      SOURCE                                            IDENTIFIER
  -------------------------------------------------------- ------------------------------------------------- ----------------------------------------------------------------------
  Antibodies                                                                                                 
  FITC Rat Anti-Mouse IgG1 (clone A85--1)                  BD Biosciences                                    Cat\# 553443; RRID:AB_394862
  FITC Rat Anti-Mouse IgG2b (clone R12--3)                 BD Biosciences                                    Cat\# 553395; RRID:AB_394833
  Goat anti Mouse IgG2c:FITC                               Bio-Rad                                           Cat\# STAR135F; RRID:AB_1102667
  FITC Rat Anti-Mouse IgG3 (clone R40--82)                 BD Biosciences                                    Cat\# 553403; RRID:AB_394840
  PerCP/Cy5.5 anti-mouse IgD Antibody                      Biolegend                                         Cat\# 405710; RRID:AB_1575113
  Anti-Human/Mouse GL7 eFluor 450                          Thermo Fisher Scientific                          Cat\# 48--5902--80; RRID:AB_10854881
  eBioscience Fixable Viability Dye eFluor 506             Thermo Fisher Scientific                          65--0866--14
  BV510 Hamster Anti-Mouse CD3e (clone 145--2c11)          BD Biosciences                                    Cat\# 563024; RRID:AB_2737959
  BV510 Rat Anti-Mouse CD4 (clone RM4--5)                  BD Biosciences                                    Cat\# 563106; RRID:AB_2687550
  BV 510 Rat Anti-Mouse Ly-6G and Ly6C (clone RB6--8C5)    BD Biosciences                                    Cat\# 563040; RRID:AB_2722496
  Brilliant Violent 510 anti-mouse F4/80 Antibody          Biolegend                                         Cat\# 123135; RRID:AB_2562622
  Brilliant Violet 605 anti-mouse IgM Antibody             Biolegend                                         Cat\# 406523; RRID:AB_2563358
  BV786 Rat Anti-Mouse CD45R/B220                          BD Biosciences                                    Cat\# 563894; RRID:AB_2738472
  Anti-Mouse CD38 Alexa Fluor 700                          Thermo Fisher Scientific                          Cat\# 56--0381--82; RRID:AB_657740
  BUV395 Rat Anti-Mouse CD19 (clone 1D3)                   BD Biosciences                                    Cat\# 563557; RRID:AB_2722495
  BV650 Rat Anti-Mouse CD19                                BD Biosciences                                    Cat\# 563235; RRID:AB_2738085
  6x-His Tag Monoclonal Antibody (HIS.H8)                  Thermo Fisher Scientific                          Cat\# MA1--21315; RRID:AB_557403
  HRP Goat anti-mouse IgG                                  Biolegend                                         Cat\# 405306; RRID:AB_315009
  Bacterial and Virus Strains                                                                                
  NEB® 5-alpha Competent *E. coli* (High Efficiency)       New England BioLabs                               C2987H
  HIV-1 Env-pseudotyped viruses                            D. Montefiori and C. LaBranche, Duke University   N/A
  Chemicals, Peptides, and Recombinant Proteins                                                              
  Poly(I:C)                                                Invivogen                                         tlrl-pic-5
  GLA-LSQ                                                  Infectious Disease Reseach Institute (IDRI)       IDRI-LS130
  Steptavidin-R-Phycoerythirin                             Prozyme                                           PJRS25
  Streptavidin-Allophycocyanin                             Prozyme                                           PJ27S
  RNaseOUT Recombinant Ribonuclease Inhibitor              Thermo Fisher Scientific                          10777019
  HotStar Taq Plus                                         QIAGEN                                            203607
  Gel Red Nucleic Acid Stain                               Biotium                                           41002
  ExoSap-IT                                                Affymetrix                                        78201
  Endoproteinase LysC                                      New England BioLabs                               P8109S
  Endo H                                                   New England BioLabs                               P0702S
  Uranyl Formate                                           Electron Microscopy Sciences                      22451
  SureBlue Reserve TMB Microwell Peroxidase Substrate      KPL                                               53--00--02
  293-Free Transfection Reagent                            Millipore Sigma                                   72181
  5x In-Fusion enzyme                                      Takara Bio                                        1805251A
  Pierce Trypsin Protease                                  Thermo Fisher Scientific                          90057
  SuperScript IV RT                                        Thermo Fisher Scientific                          18090200
  Accuprime Pfx Supermix                                   Thermo Fisher Scientific                          1244040
  Critical Commercial Assays                                                                                 
  EasySep Mouse B Cell Isolation Kit                       StemCell Technologies, Inc.                       19854
  InFusion HD Cloning Kit                                  Takara Bio                                        639649
  QIAprep Spin Miniprep Kit                                QIAGEN                                            27106
  britelite plus Reporter Gene Assay System                PerkinElmer                                       6066766
  Thrombin, Restriction Grade                              EMD Millipore                                     69671--3
  Deposited Data                                                                                             
  P-p3b3Fab + 426c Core structure                          This paper                                        Protein Data Bank, PDB ID: 6MFT
  P-p1f1Fab + eOD-GT8 structure                            This paper                                        Protein Data Bank, PDB ID: 4JPK
  Mass Spectrometry Data                                   This paper                                        PRIDE: PXD015168
  Sequence analysis code                                   This paper                                        GitHub, <https://github.com/krparks/glVRC01_sequential_immunization>
  Antibody and protein sequences                           This paper                                        GenBank, [Table S5](#SD1){ref-type="supplementary-material"}
  Experimental Models: Organisms/Strains                                                                     
  Mouse: glH-VRC01                                         [@R29]                                            N/A
  Oligonucleotides                                                                                           
  Random Primers                                           Thermo Fisher Scientific                          48190011
  GeneAmp dNTP Blend                                       Thermo Fisher Scientific                          N8080261
  Primers for PCR                                          This paper; [@R29]; [@R60]                        [Table S3](#SD1){ref-type="supplementary-material"}
  Recombinant DNA                                                                                            
  Ptt3 k vector                                            [@R57]                                            N/A
  PMN 4--341 vector                                        [@R47]                                            N/A
  Software and Algorithms                                                                                    
  Geneious (Version 8.1.9)                                 Biomatters Ltd.                                   <https://www.geneious.com>
  R (Version 3.4.1)                                        [@R52]                                            <https://www.R-project.org/>
  IMGT/V-QUEST                                             [@R10]; [@R23]                                    <http://www.imgt.org/IMGT_vquest/input>
  Tidyverse                                                [@R66]                                            <https://cran.r-project.org/web/packages/tidyverse/index.html>
  Biostrings                                               [@R50]                                            <http://bioconductor.org/packages/release/bioc/html/Biostrings.html>
  Prism 7                                                  GraphPad                                          <https://www.graphpad.com>
  seqinr                                                   [@R12]                                            N/A
  Other                                                                                                      
  Anti-PE microbeads                                       Miltenyi Biotech                                  130--048--801
  Anti-APC microbeads                                      Miltenyi Biotech                                  130--090--855
  LS Columns                                               Miltenyi Biotech                                  130--042--401
  Pierce Protein A agarose beads                           Thermo Fisher Scientific                          20334
  Anti-human IgG Fc Capture (AHC) Biosensors               ForteBio                                          18--5063
  Anti-Human Fab-CH1 2^nd^ Generation (FAB2G) Biosensors   ForteBio                                          18--5126
  MyOne Tosylactivated Dynabeads                           Thermo Fisher Scientific                          65501
  His60 Ni-Superflow Resin                                 Takara Bio                                        636660
  HiLoad 16/600 Superdex 200 pg (GE) column                GE Healthcare                                     28989335
  Superose 6 10/300 GL                                     GE Healthcare                                     17--6172--01
  Agarose Bound Galanthus Nivalis Lectin                   Vector Labs                                       AL-1243--5
  Step-Tactin SuperFlow Plus                               QIAGEN                                            30002
  HisTrap FF Column                                        GE Healthcare                                     17525501

###### Highlights

-   The germline-targeting 426c Core immunogen elicits cross-reactive VRC01-like Abs

-   Boosting with HxB2 WT Core improves the neutralizing potential of VRC01-like Abs

-   Vaccine-elicited VRC01-like Abs accommodate the loop D N276-associated glycans
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